Latest news
{{'2025-10-09T10:00:42Z' | dateFormatFilter}}
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
{{'2025-09-10T05:00:45Z' | dateFormatFilter}}
Novo Nordisk to streamline operations and reinvest for growth
{{'2025-08-15T21:23:39Z' | dateFormatFilter}}
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
